Protara Therapeutics
TARA
31 hedge funds and large institutions have $8.55M invested in Protara Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
7% more funds holding
Funds holding: 29 → 31 (+2)
0.25% less ownership
Funds ownership: 45.42% → 45.17% (-0.25%)
30% less capital invested
Capital invested by funds: $12.3M → $8.55M (-$3.71M)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$80.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$27.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.92K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$277 |
| 5 |
JP Morgan Chase
New York
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$53.8K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$30.3K |
| 3 |
Two Sigma Investments
New York
|
-$17K |
| 4 |
Millennium Management
New York
|
-$14.9K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$11.3K |
TARA Hedge Fund Activity: Q3 2023 in Review
31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2023, worth a combined $8.55M — down 30% from $12.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TARA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 9 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $80.1K. The largest seller was Renaissance Technologies, cutting an estimated $53.8K.
- 31 institutional investors held Protara Therapeutics (TARA) as of Q3 2023, up from 29 in Q2 2023.
- Funds reported $8.55M of Protara Therapeutics stock for Q3 2023, down 30% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q3 2023 and 2 closed out, a net change of +2 holders.
- The largest Protara Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $80.1K added.
- The largest Protara Therapeutics seller in Q3 2023 was Renaissance Technologies, an estimated $53.8K sold.
Based on aggregated 13F filings for Q3 2023.